Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Obsessive-compulsive disorder (OCD) is a debilitating neuropsychiatric condition estimated to afflict 1-3% of the world population. The estimated financial impact in the treatment and management of OCD is in the billions of dollars annually in the US alone. At present there is a marked lack of evidence on the specific causes of OCD. Current hypotheses largely focus on the serotonin (5-HT) system on the basis of the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in alleviating symptoms of patients with OCD, yet a considerable fraction of patients are non-responsive or minimally responsive to these agents. Despite this fact, SSRIs have remained the primary pharmacological treatment avenue for OCD. In recent years, multiple lines of evidence have implicated glutamatergic synaptic dysfunction within the cortico-striatal-thalamo-cortical (CSTC) brain circuit in the etiology of OCD and related disorders, thereby prompting intensified effort in the development and evaluation of agents that modulate glutamatergic neurotransmission for the treatment of OCD. With this in mind, here we review the following topics with respect to synaptic dysfunction and the neural circuitry underlying OCD: (1) evidence supporting the critical involvement of the CSTC circuit, (2) genetic studies supporting the involvement of glutamatergic dysfunction, (3) insights from genetic animal models of OCD, and (4) preliminary findings with glutamatergic neurotransmission-modulating agents in the treatment of OCD. Given the putative mechanistic overlap between OCD and the broader OC-spectrum of disorders, unraveling the synaptic basis of OCD has potential to translate into more effective treatments for an array of poorly understood human disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Swedo, S. E., Leonard, H. L., Garvey, M., Mittleman, B., Allen, A. J., Perlmutter, S., Dow, S., Zamkoff, J., Dubbert, B. K., & Lougee, L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.2.264 · Cited by 1,534
Baxter, L. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090009002 · Cited by 1,293
Frontal–subcortical neuronal circuits and clinical neuropsychiatry
Tekin, S., & Cummings, J. L. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00428-2 · Cited by 1,240
Menzies, L., Chamberlain, S. R., Laird, A. R., Thelen, S. M., Sahakian, B. J., & Bullmore, E. T. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.09.005 · Cited by 1,190
NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159 · cited 2×
“Of particular interest, the subunit composition of NMDA receptors is dynamically regulated during development and is important in determining the functional properties of the receptor [81].”
BackgroundFoa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
The Basal Ganglia and Chunking of Action Repertoires
Graybiel, A. M. (1998) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1998.3843 · Cited by 1,042 · cited 1×
“The release of such cognitive and motor sequences or “action chunks” become pathological because they are no longer under the control of intent despite being consciously performed [55].”
BackgroundPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Rauch, S. L. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010062008 · Cited by 880
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852 · cited 4×
“Recent evidence from the SAPAP3 null mouse demonstrates the importance of this protein in regulating cortico-striatal synaptic function [96].”
BackgroundInfluentialSelf-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Fear and the brain: where have we been, and where are we going?
LeDoux, J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00282-0 · Cited by 782
Neurotransmission in the rat amygdala related to fear and anxiety
Davis, M., Rainnie, D., & Cassell, M. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90106-6 · Cited by 771 · cited 1×
“Altered amygdala volume and dysfunctional amygdala activation have been reported in OCD patients [71-73], and the amygdala has a well established role in the expression of fear and anxiety [74, 75].”
BackgroundMetabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Sturm, V., Lenartz, D., Koulousakis, A., Treuer, H., Herholz, K., Klein, J. C., & Klosterkötter, J. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2003.09.003 · Cited by 567 · cited 1×
“Additional studies have shown effectiveness of DBS in the nucleus accumbens (NAc) region in OCD [61, 62], and an in-”
BackgroundHyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards
Peciña, S., Cagniard, B., Berridge, K. C., Aldridge, J. W., & Zhuang, X. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09395.2003 · Cited by 551
Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.12.1560 · Cited by 541
Kim, E., Naisbitt, S., Hsueh, Y.-P., Rao, A., Rothschild, A., Craig, A. M., & Sheng, M. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.3.669 · Cited by 516 · cited 1×
“The SAPAP family of proteins is found at excitatory synapses and was originally identified as a family of proteins that interacts with postsynaptic density-95 (PSD95) and Shank family members [121-123].”
BackgroundCompulsive hoarding: current status of the research
Steketee, G., & Frost, R. (2003) · Clinical Psychology Review · doi:10.1016/j.cpr.2003.08.002 · Cited by 498 · cited 1×
“ERP therapy [25].”
Modification of expectations in cases with obsessional rituals
Meyer, V. (1966) · Behaviour Research and Therapy · doi:10.1016/0005-7967(66)90023-4 · Cited by 461
Kanai, Y., & Hediger, M. A. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1146-4 · Cited by 450 · cited 1×
“Of particular interest, SLC1A1 is highly expressed in brain regions comprising CSTC circuits [87, 88].”
BackgroundHigh prevalence of obsessive–compulsive symptoms in patients with Sydenham's chorea
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.2.246 · Cited by 421
LAPLANE, D., LEVASSEUR, M., PILLON, B., DUBOIS, B., BAULAC, M., MAZOYER, B., DINH, S. T., SETTE, G., DANZE, F., & BARON, J. C. (1989) · Brain · doi:10.1093/brain/112.3.699 · Cited by 415
Hoxb8 Is Required for Normal Grooming Behavior in Mice
Greer, J. M., & Capecchi, M. R. (2002) · Neuron · doi:10.1016/s0896-6273(01)00564-5 · Cited by 401 · cited 2×
“To address the role of Hoxb8 in the adult brain, Greer and Capecchi [106] created mice homozygous for a loss-of-function allele of Hoxb8.”
BackgroundFranklin, M. E., Abramowitz, J. S., Kozak, M. J., Levitt, J. T., & Foa, E. B. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.4.594 · Cited by 387
Saxena, S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00082-2 · Cited by 379 · cited 1×
“clomipramine treatment [41-45], but also with behavioral therapy [43, 46] and neurosurgical lesion [47].”
BackgroundThe psychological treatment of obsessive-compulsive disorder
Abramowitz, J. S. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100702 · Cited by 371
Takeuchi, M., Hata, Y., Hirao, K., Toyoda, A., Irie, M., & Takai, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11943 · Cited by 359
Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder
Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050776 · Cited by 358 · cited 1×
“nounced treatment response with DCS [160], at least for initial sessions [161], while the third study did not find evidence of improvements with DCS [162].”
ResultToward a Neurodevelopmental Model of Obsessive–Compulsive Disorder
Rosenberg, D. R., & Keshavan, M. S. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00443-5 · Cited by 355
Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder
Szeszko, P. R., Robinson, D., Alvir, J. M. J., Bilder, R. M., Lencz, T., Ashtari, M., Wu, H., & Bogerts, B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.10.913 · Cited by 346 · cited 1×
“Altered amygdala volume and dysfunctional amygdala activation have been reported in OCD patients [71-73], and the amygdala has a well established role in the expression of fear and anxiety [74, 75].”
BackgroundGlutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · cited 1×
“[34], and in support of this model, a recent small study demonstrated elevated CSF glutamate levels in adult OCD patients compared to normal controls [78].”
ResultPathophysiology of obsessive–compulsive disorder
Aouizerate, B., Guehl, D., Cuny, E., Rougier, A., Bioulac, B., Tignol, J., & Burbaud, P. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.02.004 · Cited by 341
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 2×
“[129, 130], 7 out of 13 patients”
Berridge, K. C., Aldridge, J. W., Houchard, K. R., & Zhuang, X. (2005) · BMC Biology · doi:10.1186/1741-7007-3-4 · Cited by 309
Karayiorgou, M., Altemus, M., Galke, B. L., Goldman, D., Murphy, D. L., Ott, J., & Gogos, J. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4572 · Cited by 304 · cited 1×
“In light of the evidence that low COMT activity is a risk factor in human OCD, specifically in males [17, 118-120], and”
Background(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.4.568 · Cited by 301 · cited 1×
“hypothesized the involvement of NMDA receptor gene variations in OCD based on neuroimaging findings of deficient striatal activation during learning tasks in OCD patients [82], thereby demonstrating the potential utility of integrating neuroimaging and genetic studies.”
BackgroundBehavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis
Kobak, K. A., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., & Henk, H. J. (1998) · Psychopharmacology · doi:10.1007/s002130050558 · Cited by 276
Dickel, D. E., Veenstra-VanderWeele, J., Cox, N. J., Wu, X., Fischer, D. J., Van Etten-Lee, M., Himle, J. A., Leventhal, B. L., Cook, E. H., & Hanna, G. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.778 · Cited by 274 · cited 2×
“incomplete coverage of the SLC1A1 gene region, and indeed association of SLC1A1 with OCD became apparent in a more thorough study by the same group in 2006 [84].”
BackgroundResultMonahan, J. B., Handelmann, G. E., Hood, W. F., & Cordi, A. A. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90571-6 · Cited by 257
Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213 · cited 2×
“The tricyclic antidepressant clomipramine is often still considered a first-line drug in treating OCD symptoms, and there is some evidence to suggest superior efficacy relative to SSRIs; however, clomipramine is less well tolerated than the SSRIs and causes a broad range of side effects—likely due to anticholinergic e…”
BackgroundSapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study
Bienvenu, O. J., Wang, Y., Shugart, Y. Y., Welch, J. M., Grados, M. A., Fyer, A. J., Rauch, S. L., McCracken, J. T., Rasmussen, S. A., Murphy, D. L., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30897 · Cited by 207
Self-citationArnold, P., Rosenberg, D., Mundo, E., Tharmalingam, S., Kennedy, J., & Richter, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1847-1 · Cited by 202 · cited 1×
“[79] provided the first report of a positive association between a glutamatergic system gene and OCD.”
BackgroundD-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8480 · Cited by 200
Grant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197 · cited 1×
“An open-label trial of riluzole in children with treatment resistant OCD produced qualitatively similar results, with 4 out of 6 patients classified as riluzole treatment responders [132].”
ResultMultiple rare SAPAP3 missense variants in trichotillomania and OCD
Züchner, S., Wendland, J. R., Ashley-Koch, A. E., Collins, A. L., Tran-Viet, K. N., Quinn, K., Timpano, K. C., Cuccaro, M. L., Pericak-Vance, M. A., Steffens, D. C., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.83 · Cited by 196
Self-citationAssociation of the SLC1A1 glutamate transporter gene and obsessive‐compulsive disorder
Stewart, S. E., Fagerness, J. A., Platko, J., Smoller, J. W., Scharf, J. M., Illmann, C., Jenike, E., Chabane, N., Leboyer, M., Delorme, R., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30533 · Cited by 182 · cited 1×
“A third independent investigation [89] also confirmed an association between OCD and SLC1A1 for both single marker and haplotype single nucleotide polymorphisms (SNPs) in the 3’ region of the gene, consistent with the earlier studies [83,”
ResultRiluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177 · cited 1×
“For a very recent comprehensive review on riluzole’s mechanism of action and use in psychiatric conditions see [135].”
BackgroundCampbell, K. M., de Lecea, L., Severynse, D. M., Caron, M. G., McGrath, M. J., Sparber, S. B., Sun, L.-Y., & Burton, F. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05044.1999 · Cited by 170 · cited 1×
“D1CT-7 mice exhibited repetitive biting of littermates that was unrelated to aggression, repetitive leaping, and extended bouts of repetition during normal behaviors [101].”
BackgroundCurrent animal models of obsessive compulsive disorder: a critical review
Joel, D. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.006 · Cited by 168
Compulsive behavior in the 5-HT2C receptor knockout mouse
Chou-Green, J. M., Holscher, T. D., Dallman, M. F., & Akana, S. F. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00047-7 · Cited by 143 · cited 1×
“[108] characterized compulsive aspects of 5-HT2C null mouse behavior that were more representative of OCD-like behaviors.”
BackgroundSerotoninergic mechanisms in the treatment of obsessive–compulsive disorder
Goddard, A. W., Shekhar, A., Whiteman, A. F., & McDougle, C. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.009 · Cited by 112
Amygdala responses to human faces in obsessive-compulsive disorder
Cannistraro, P. A., Wright, C. I., Wedig, M. M., Martis, B., Shin, L. M., Wilhelm, S., & Rauch, S. L. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.09.029 · Cited by 100 · cited 1×
“Altered amygdala volume and dysfunctional amygdala activation have been reported in OCD patients [71-73], and the amygdala has a well established role in the expression of fear and anxiety [74, 75].”
BackgroundThe current status of association studies in obsessive-compulsive disorder
Hemmings, S. M. J., & Stein, D. J. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.011 · Cited by 83 · cited 2×
“transmitter systems in OCD (though many of the findings are controversial), and an extensive review of these studies can be found elsewhere [77].”
BackgroundVeenstra-VanderWeele, J., Kim, S.-J., Gonen, D., Hanna, G. L., Leventhal, B. L., & Cook, E. H. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000806 · Cited by 74
Kim, S. A., Kim, J. H., Park, M., Cho, I. H., & Yoo, H. J. (2007) · Neuroscience Research · doi:10.1016/j.neures.2007.03.002 · Cited by 49 · cited 1×
“Notably, there is increasing evidence for GRIK2 variations associated with autism [92-94], a disorder with manifestations that include compulsive-repetitive behavior similar to OCD.”
Background
Cited by
BDNF signaling in context: From synaptic regulation to psychiatric disorders
Wang, C. S., Kavalali, E. T., & Monteggia, L. M. (2022) · Cell · doi:10.1016/j.cell.2021.12.003 · Cited by 607
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“We (Pittenger et al., 2006) and others (Carlsson, 2000, 2001; Rosenberg & Hanna, 2000; Rosenberg et al., 2000; Chakrabarty et al., 2005; Ting & Feng, 2008) have proposed that abnormalities in glutamate neurotransmission and homeostasis, especially in the CSTC circuitry, may contribute to OCD.”
BackgroundThe role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
“…animal models which suggest that post-synaptic dysfunction in glutamate signalling represents the most likely candidate mechanism at the molecular level to explain the higher order changes seen in CSTC glutamate transmission (for a recent review discussing this hypothesis see Ting and Feng, 2008).”
InfluentialGhaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Ting, J. T., & Feng, G. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.04.010 · Cited by 143
Self-citation
Metadata
- Authors
- Ting, J. T., & Feng, G.
- Venue
- Current Chemical Genomics
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-12-19
- Volume
- 2
- Pages
- 62-75
- ISSN
- 1875-3973 (ISSN-L)
- OpenAlex
- W2130722072
- Cited by
- 125
- References
- 58
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.